How much funding has Immunai raised?

Immunai has raised $275.0M across 3 funding rounds.

Immunai Analysis: $275M Raised

What is Immunai?

Immunai specializes in mapping the immune system at an unprecedented scale and resolution. Their unique approach integrates multi-omic data with advanced machine learning to enhance drug discovery and development. This enables biopharmaceutical companies to make informed decisions, reducing risks and accelerating the development of immune-related therapeutics.

Employees

51-200

Founded

2018

Industry

HealthTech, Biotech, AI/ML

Product Features & Capabilities

Target Discovery for identifying novel disease-linked targets
Preclinical Evaluation to prioritize promising drug candidates
Clinical Trial Optimization for understanding drug mechanisms and patient groups
Multi-Omic Immune Sequencing for comprehensive immune profiling
AMICA database integration for enhanced analytical insights.

Use Cases

Identify high-impact therapeutic targets for drug development; Prioritize drug candidates based on preclinical data; Optimize clinical trials by understanding patient responses; Generate high-quality multi-omic data from samples; Validate hypotheses using functional genomics.

How much Immunai raised

Series A - $60 million

February 11, 2021

Lead Investor: Catalio Capital Management, Charles and Lynn Schusterman Family Philanthropies, Dexcel Pharma, Duquesne Family Office

Series B - $215 million

October 27, 2021

Lead Investor: Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, among others

Other Considerations

Partnered with top biopharmaceutical companies and research institutions; Offers a unique end-to-end workflow for drug development; Utilizes the world's largest immune-focused single-cell database.

See something that needs updating? Suggest edits to this profile.